Overview

Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus

Status:
Completed

Trial end date:
2013-07-01

Target enrollment:

Participant gender:

Summary

Insulin-naive subjects with Type 2 Diabetes Mellitus who are sub-optimally controlled on either maximum tolerated dose of metformin or maximum tolerated dose of metformin plus one or two other oral anti-diabetic medications will have either Prandial Technosphere® Insulin or Technosphere Powder (placebo) added to their oral antidiabetic drugs.

Phase:

Phase 3

Details

Lead Sponsor:

Mannkind Corporation

Treatments:

Insulin
Insulin, Globin Zinc